



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

18 May 2012  
EMA/328312/2012  
Human Medicines Development and Evaluation

## Public statement

---

### Clopidogrel Acino Pharma GmbH (clopidogrel)

#### Withdrawal of the marketing authorisation in the European Union

On 21 September 2009 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Clopidogrel Acino Pharma GmbH (clopidogrel). Clopidogrel Acino Pharma GmbH was approved for the prevention of atherothrombotic events in patients with peripheral vascular diseases or who have had a stroke or myocardial infarction.

The marketing authorisation holder (MAH) responsible for Clopidogrel Acino Pharma GmbH was Acino Pharma GmbH.

The European Commission was notified by letter dated 11 January 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation for Clopidogrel Acino Pharma GmbH for commercial reasons.

On 13 February 2012 the European Commission issued a decision to withdraw the marketing authorisation for Clopidogrel Acino Pharma GmbH. Pursuant to this decision the European Public Assessment Report for Clopidogrel Acino Pharma GmbH will be updated to reflect the fact that the marketing authorisation is no longer valid.

